Skip to content

Study · Non-randomized trial · n = 10 · 2017

6 results

Liraglutide Treatment May Affect Renin and Aldosterone Release.

Sedman T, Heinla K, Vasar E, Volke V

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme14 Jun 2016Cited by 18 (Europe PMC)

PMID27300475 (opens in a new tab)DOI10.1055/s-0042-109065 (opens in a new tab)PepBankPUB-27300475
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In healthy volunteers, aldosterone tended to fall after acute liraglutide administration, but the change was not statistically significant.

    In plain wordsIn healthy adults, aldosterone tended to fall after one liraglutide dose, but the change was not statistically significant.

    Peptide
    Liraglutide
    Outcome
    No significant changeAldosterone after acute liraglutide
    Study

    n = 10

    Comparator
    Baseline
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    0.6 mg dailyAs given in this study (human).

    Source sentences

    Summary
    aldosterone tended to be suppressed (albeit not statistically different) after acute administration of liraglutide
    2 context sentences
    Summary · context
    Ten healthy volunteers were recruited into a single group open-label clinical trial.
    Summary · context
    Each participant was tested for baseline levels, and after acute and chronic treatment with 0.6 mg liraglutide daily.
  2. 02HumanNon-randomized trialEfficacy outcome

    In healthy volunteers, aldosterone increased after chronic liraglutide dosing, and the difference between acute and chronic dosing was statistically significant.

    In plain wordsIn healthy adults, aldosterone was higher after long-term liraglutide than after a single dose.

    Peptide
    Liraglutide
    Outcome
    IncreaseAldosterone after chronic liraglutide versus acute
    Study

    n = 10

    Comparator
    Acute dosing
    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    0.6 mg dailyAs given in this study (human).

    Source sentences

    Summary
    and increased after chronic dosing; the difference was statistically significant when compared between acute and chronic dosing.
    2 context sentences
    Summary · context
    Ten healthy volunteers were recruited into a single group open-label clinical trial.
    Summary · context
    Each participant was tested for baseline levels, and after acute and chronic treatment with 0.6 mg liraglutide daily.
  3. 03HumanNon-randomized trialEfficacy outcome

    In healthy volunteers treated with liraglutide, changes in aldosterone levels followed changes in renin concentrations.

    In plain wordsIn healthy adults, aldosterone changes followed renin changes during liraglutide treatment.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedRenin concentration
    Study

    n = 10

    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    0.6 mg dailyAs given in this study (human).

    Source sentences

    Summary
    Changes in aldosterone levels followed the changes in renin concentrations and the aldosterone-to-renin ratio remained stable.
    2 context sentences
    Summary · context
    Ten healthy volunteers were recruited into a single group open-label clinical trial.
    Summary · context
    Each participant was tested for baseline levels, and after acute and chronic treatment with 0.6 mg liraglutide daily.
  4. 04HumanNon-randomized trialEfficacy outcome

    In healthy volunteers, the aldosterone-to-renin ratio remained stable during liraglutide treatment.

    In plain wordsIn healthy adults, the aldosterone-to-renin ratio stayed stable during liraglutide treatment.

    Peptide
    Liraglutide
    Outcome
    No significant changeAldosterone-to-renin ratio
    Study

    n = 10

    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    0.6 mg dailyAs given in this study (human).

    Source sentences

    Summary
    Changes in aldosterone levels followed the changes in renin concentrations and the aldosterone-to-renin ratio remained stable.
    2 context sentences
    Summary · context
    Ten healthy volunteers were recruited into a single group open-label clinical trial.
    Summary · context
    Each participant was tested for baseline levels, and after acute and chronic treatment with 0.6 mg liraglutide daily.
  5. 05HumanNon-randomized trialEfficacy outcome

    In healthy volunteers, liraglutide caused no statistically significant difference in ACTH levels.

    In plain wordsIn healthy adults, liraglutide did not significantly change ACTH levels.

    Peptide
    Liraglutide
    Outcome
    No significant changeACTH level
    Study

    n = 10

    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    0.6 mg dailyAs given in this study (human).

    Source sentences

    Summary
    No statistically significant differences were observed in ACTH or cortisol levels.
    2 context sentences
    Summary · context
    Ten healthy volunteers were recruited into a single group open-label clinical trial.
    Summary · context
    Each participant was tested for baseline levels, and after acute and chronic treatment with 0.6 mg liraglutide daily.
  6. 06HumanNon-randomized trialEfficacy outcome

    In healthy volunteers, liraglutide caused no statistically significant difference in cortisol levels.

    In plain wordsIn healthy adults, liraglutide did not significantly change cortisol levels.

    Peptide
    Liraglutide
    Outcome
    No significant changeCortisol level
    Study

    n = 10

    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    0.6 mg dailyAs given in this study (human).

    Source sentences

    Summary
    No statistically significant differences were observed in ACTH or cortisol levels.
    2 context sentences
    Summary · context
    Ten healthy volunteers were recruited into a single group open-label clinical trial.
    Summary · context
    Each participant was tested for baseline levels, and after acute and chronic treatment with 0.6 mg liraglutide daily.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT02089256

Effect of Repeated Administration of Liraglutide on Insulinogenic Indices

University of Tartun = 10Jun 2014 to Mar 2015

Healthy

Trial pageClinicalTrials.govUpdated 1 Apr 2015

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.